Contingency Management for Treatment of Cannabis Use Disorder in Co-Occurring Mental Health Disorders: A Systematic Review.

Autor: Rodas JD; Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada.; Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada., Sorkhou M; Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada.; Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada., George TP; Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada.; Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada.
Jazyk: angličtina
Zdroj: Brain sciences [Brain Sci] 2022 Dec 23; Vol. 13 (1). Date of Electronic Publication: 2022 Dec 23.
DOI: 10.3390/brainsci13010036
Abstrakt: Amongst individuals with a mental health disorder, a comorbid diagnosis of cannabis use disorder (CUD) is associated with numerous adverse consequences, including more severe symptom profiles, poorer treatment response, and reduced psychosocial functioning. Contingency management (CM), a method to specifically reinforce target behavior attainment (e.g., substance use abstinence), may provide an effective intervention in treating cannabis use in patients with a dual diagnosis of CUD and a mental health disorder. A systematic search examining the effects of CM on cannabis use, clinical, cognitive, and psychosocial outcomes in patients with a mental health disorder on PubMed, PsycINFO, and EMBASE databases up to November 2022 was performed. Six studies met inclusion criteria for our review. We found CM to be efficacious in producing cannabis use reductions and abstinence amongst individuals with a psychotic-spectrum or major depressive disorder. Additional longitudinal studies with larger sample sizes, other psychiatric populations, and longer follow-up periods are needed to evaluate the sustained effects of CM.
Competing Interests: T.P.G. has provided consultancy to Frutarom and Sanford Burnham Prebys. T.P.G. is also the Chair of the Scientific Advisory Committee of CCSA and Co-Principal Editor of Neuropsychopharmacology (NPP).
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje